Quantitative analysis of genitourinary toxicity after iodine-125 brachytherapy for localized prostate cancer: Followup of the International Prostate Symptom Score and Overactive Bladder Symptom Score

Masanori Sakayori, Toshio Ohashi, Tetsuo Momma, Tomoya Kaneda, Shuichi Nishimura, Shinya Sutani, Shoji Yamashita, Naoyuki Shigematsu

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Purpose: To analyze genitourinary toxicity by followup of the International Prostate Symptom Score (IPSS) and Overactive Bladder Symptom Score (OABSS) after prostate brachytherapy. Methods and Materials: Six hundred eighty patients were treated with iodine-125 brachytherapy for localized prostate cancer. IPSS, OABSS, and two categories of IPSS questions (storage symptom score [IPSS-S] and voiding symptom score [IPSS-V]) were evaluated. Results: The median followup was 54 months (range, 24-108). All scales showed rapid increases followed by gradual decreases. The median times to IPSS peak and resolution were 1 and 6 months, respectively. The resolution rates of IPSS, IPSS-S, IPSS-V, and OABSS at the last followup were 84.2%, 86.3%, 89.5%, and 83.0%, respectively. The difference between IPSS baseline and peak was greater for larger preimplant prostate volumes (≥25 mL, p = 0.004). The time to resolution was longer for higher biologic effective dose (BED) (≥210 Gy, p = 0.019 [IPSS]), in those with larger prostate volumes (≥25 mL, p = 0.025 [OABSS]), in younger patients (younger than 70 years, p = 0.043 [IPSS-S]), and in those with androgen deprivation therapy (ADT) use (p = 0.049 [IPSS-V]). Urge incontinence, included in the OABSS, was observed more commonly in older patients (75 years and older, p = 0.018), with ADT use (p < 0.001), and for higher BED (≥210 Gy, p = 0.006). Conclusions: The IPSS and OABSS showed similar patterns of change. Urinary symptoms improved more rapidly in those with high baseline IPSS levels. The OABSS was useful for following urinary symptoms after prostate brachytherapy. Age, ADT use, preimplant prostate volume, and BED were significantly associated with urinary outcomes.

Original languageEnglish
JournalBrachytherapy
DOIs
Publication statusAccepted/In press - 2017 Mar 2

Fingerprint

Overactive Urinary Bladder
Brachytherapy
Iodine
Prostate
Prostatic Neoplasms
Androgens
Urge Urinary Incontinence

Keywords

  • Brachytherapy
  • IPSS
  • OABSS
  • Prostate cancer
  • Toxicity

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging

Cite this

Quantitative analysis of genitourinary toxicity after iodine-125 brachytherapy for localized prostate cancer : Followup of the International Prostate Symptom Score and Overactive Bladder Symptom Score. / Sakayori, Masanori; Ohashi, Toshio; Momma, Tetsuo; Kaneda, Tomoya; Nishimura, Shuichi; Sutani, Shinya; Yamashita, Shoji; Shigematsu, Naoyuki.

In: Brachytherapy, 02.03.2017.

Research output: Contribution to journalArticle

@article{55c15602d39149699dc5b82c3d98aca6,
title = "Quantitative analysis of genitourinary toxicity after iodine-125 brachytherapy for localized prostate cancer: Followup of the International Prostate Symptom Score and Overactive Bladder Symptom Score",
abstract = "Purpose: To analyze genitourinary toxicity by followup of the International Prostate Symptom Score (IPSS) and Overactive Bladder Symptom Score (OABSS) after prostate brachytherapy. Methods and Materials: Six hundred eighty patients were treated with iodine-125 brachytherapy for localized prostate cancer. IPSS, OABSS, and two categories of IPSS questions (storage symptom score [IPSS-S] and voiding symptom score [IPSS-V]) were evaluated. Results: The median followup was 54 months (range, 24-108). All scales showed rapid increases followed by gradual decreases. The median times to IPSS peak and resolution were 1 and 6 months, respectively. The resolution rates of IPSS, IPSS-S, IPSS-V, and OABSS at the last followup were 84.2{\%}, 86.3{\%}, 89.5{\%}, and 83.0{\%}, respectively. The difference between IPSS baseline and peak was greater for larger preimplant prostate volumes (≥25 mL, p = 0.004). The time to resolution was longer for higher biologic effective dose (BED) (≥210 Gy, p = 0.019 [IPSS]), in those with larger prostate volumes (≥25 mL, p = 0.025 [OABSS]), in younger patients (younger than 70 years, p = 0.043 [IPSS-S]), and in those with androgen deprivation therapy (ADT) use (p = 0.049 [IPSS-V]). Urge incontinence, included in the OABSS, was observed more commonly in older patients (75 years and older, p = 0.018), with ADT use (p < 0.001), and for higher BED (≥210 Gy, p = 0.006). Conclusions: The IPSS and OABSS showed similar patterns of change. Urinary symptoms improved more rapidly in those with high baseline IPSS levels. The OABSS was useful for following urinary symptoms after prostate brachytherapy. Age, ADT use, preimplant prostate volume, and BED were significantly associated with urinary outcomes.",
keywords = "Brachytherapy, IPSS, OABSS, Prostate cancer, Toxicity",
author = "Masanori Sakayori and Toshio Ohashi and Tetsuo Momma and Tomoya Kaneda and Shuichi Nishimura and Shinya Sutani and Shoji Yamashita and Naoyuki Shigematsu",
year = "2017",
month = "3",
day = "2",
doi = "10.1016/j.brachy.2017.04.241",
language = "English",
journal = "Brachytherapy",
issn = "1538-4721",
publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - Quantitative analysis of genitourinary toxicity after iodine-125 brachytherapy for localized prostate cancer

T2 - Followup of the International Prostate Symptom Score and Overactive Bladder Symptom Score

AU - Sakayori, Masanori

AU - Ohashi, Toshio

AU - Momma, Tetsuo

AU - Kaneda, Tomoya

AU - Nishimura, Shuichi

AU - Sutani, Shinya

AU - Yamashita, Shoji

AU - Shigematsu, Naoyuki

PY - 2017/3/2

Y1 - 2017/3/2

N2 - Purpose: To analyze genitourinary toxicity by followup of the International Prostate Symptom Score (IPSS) and Overactive Bladder Symptom Score (OABSS) after prostate brachytherapy. Methods and Materials: Six hundred eighty patients were treated with iodine-125 brachytherapy for localized prostate cancer. IPSS, OABSS, and two categories of IPSS questions (storage symptom score [IPSS-S] and voiding symptom score [IPSS-V]) were evaluated. Results: The median followup was 54 months (range, 24-108). All scales showed rapid increases followed by gradual decreases. The median times to IPSS peak and resolution were 1 and 6 months, respectively. The resolution rates of IPSS, IPSS-S, IPSS-V, and OABSS at the last followup were 84.2%, 86.3%, 89.5%, and 83.0%, respectively. The difference between IPSS baseline and peak was greater for larger preimplant prostate volumes (≥25 mL, p = 0.004). The time to resolution was longer for higher biologic effective dose (BED) (≥210 Gy, p = 0.019 [IPSS]), in those with larger prostate volumes (≥25 mL, p = 0.025 [OABSS]), in younger patients (younger than 70 years, p = 0.043 [IPSS-S]), and in those with androgen deprivation therapy (ADT) use (p = 0.049 [IPSS-V]). Urge incontinence, included in the OABSS, was observed more commonly in older patients (75 years and older, p = 0.018), with ADT use (p < 0.001), and for higher BED (≥210 Gy, p = 0.006). Conclusions: The IPSS and OABSS showed similar patterns of change. Urinary symptoms improved more rapidly in those with high baseline IPSS levels. The OABSS was useful for following urinary symptoms after prostate brachytherapy. Age, ADT use, preimplant prostate volume, and BED were significantly associated with urinary outcomes.

AB - Purpose: To analyze genitourinary toxicity by followup of the International Prostate Symptom Score (IPSS) and Overactive Bladder Symptom Score (OABSS) after prostate brachytherapy. Methods and Materials: Six hundred eighty patients were treated with iodine-125 brachytherapy for localized prostate cancer. IPSS, OABSS, and two categories of IPSS questions (storage symptom score [IPSS-S] and voiding symptom score [IPSS-V]) were evaluated. Results: The median followup was 54 months (range, 24-108). All scales showed rapid increases followed by gradual decreases. The median times to IPSS peak and resolution were 1 and 6 months, respectively. The resolution rates of IPSS, IPSS-S, IPSS-V, and OABSS at the last followup were 84.2%, 86.3%, 89.5%, and 83.0%, respectively. The difference between IPSS baseline and peak was greater for larger preimplant prostate volumes (≥25 mL, p = 0.004). The time to resolution was longer for higher biologic effective dose (BED) (≥210 Gy, p = 0.019 [IPSS]), in those with larger prostate volumes (≥25 mL, p = 0.025 [OABSS]), in younger patients (younger than 70 years, p = 0.043 [IPSS-S]), and in those with androgen deprivation therapy (ADT) use (p = 0.049 [IPSS-V]). Urge incontinence, included in the OABSS, was observed more commonly in older patients (75 years and older, p = 0.018), with ADT use (p < 0.001), and for higher BED (≥210 Gy, p = 0.006). Conclusions: The IPSS and OABSS showed similar patterns of change. Urinary symptoms improved more rapidly in those with high baseline IPSS levels. The OABSS was useful for following urinary symptoms after prostate brachytherapy. Age, ADT use, preimplant prostate volume, and BED were significantly associated with urinary outcomes.

KW - Brachytherapy

KW - IPSS

KW - OABSS

KW - Prostate cancer

KW - Toxicity

UR - http://www.scopus.com/inward/record.url?scp=85019571375&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85019571375&partnerID=8YFLogxK

U2 - 10.1016/j.brachy.2017.04.241

DO - 10.1016/j.brachy.2017.04.241

M3 - Article

C2 - 28552494

AN - SCOPUS:85019571375

JO - Brachytherapy

JF - Brachytherapy

SN - 1538-4721

ER -